

Manuela Basso

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6835361/publications.pdf>

Version: 2024-02-01

60
papers

2,841
citations

201674

27
h-index

175258

52
g-index

63
all docs

63
docs citations

63
times ranked

5274
citing authors

#	ARTICLE	IF	CITATIONS
1	Skeletal Muscle Pathogenesis in Polyglutamine Diseases. <i>Cells</i> , 2022, 11, 2105.	4.1	2
2	ClC-2-like Chloride Current Alterations in a Cell Model of Spinal and Bulbar Muscular Atrophy, a Polyglutamine Disease. <i>Journal of Molecular Neuroscience</i> , 2021, 71, 662-674.	2.3	13
3	Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia. <i>Brain</i> , 2021, 144, 3710-3726.	7.6	13
4	Huntingtin-mediated axonal transport requires arginine methylation by PRMT6. <i>Cell Reports</i> , 2021, 35, 108980.	6.4	20
5	Neither a Novel Tau Proteinopathy nor an Expansion of a Phenotype: Reappraising Clinicopathology-Based Nosology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7292.	4.1	7
6	Decoding distinctive features of plasma extracellular vesicles in amyotrophic lateral sclerosis. <i>Molecular Neurodegeneration</i> , 2021, 16, 52.	10.8	19
7	Motor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 723871.	3.4	5
8	NURR1 and ERR1 Modulate the Expression of Genes of a <i>DRD2</i> Coexpression Network Enriched for Schizophrenia Risk. <i>Journal of Neuroscience</i> , 2020, 40, 932-941.	3.6	19
9	Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment. <i>Genetics in Medicine</i> , 2020, 22, 1851-1862.	2.4	30
10	A case report of late-onset cerebellar ataxia associated with a rare p.R342W TGM6 (SCA35) mutation. <i>BMC Neurology</i> , 2020, 20, 408.	1.8	3
11	Focus on the heterogeneity of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 485-495.	1.7	32
12	Increased transcription of transglutaminase 1 mediates neuronal death in in vitro models of neuronal stress and A β 1-42-mediated toxicity. <i>Neurobiology of Disease</i> , 2020, 140, 104849.	4.4	10
13	Rapid Nickel-based Isolation of Extracellular Vesicles from Different Biological Fluids. <i>Bio-protocol</i> , 2020, 10, e3512.	0.4	7
14	Polyglutamine-Expanded Androgen Receptor Alteration of Skeletal Muscle Homeostasis and Myonuclear Aggregation Are Affected by Sex, Age and Muscle Metabolism. <i>Cells</i> , 2020, 9, 325.	4.1	21
15	Transglutaminases, neuronal cell death and neural repair: implications for traumatic brain injury and therapeutics. <i>Current Opinion in Neurology</i> , 2019, 32, 796-801.	3.6	6
16	Designing Dual Transglutaminase/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. <i>ChemMedChem</i> , 2018, 13, 227-230.	3.2	13
17	T197. A DRD2 CO-EXPRESSION GENE SET ENRICHED FOR SCHIZOPHRENIA RISK GENES IS CHARACTERIZED BY A COMMON TRANSCRIPTIONAL REGULATION INVOLVING NURR1 TRANSCRIPTION FACTOR. <i>Schizophrenia Bulletin</i> , 2018, 44, S193-S193.	4.3	0
18	A14-Arginine methylation of huntingtin is a novel post-translational modification that impacts huntington's disease pathogenesis. , 2018, , .		0

#	ARTICLE	IF	CITATIONS
19	Role of Extracellular Vesicles in Amyotrophic Lateral Sclerosis. <i>Frontiers in Neuroscience</i> , 2018, 12, 574.	2.8	47
20	Striatal Mutant Huntingtin Protein Levels Decline with Age in Homozygous Huntingtin TM s Disease Knock-In Mouse Models. <i>Journal of Huntington's Disease</i> , 2018, 7, 137-150.	1.9	14
21	Altered ionic currents and amelioration by IGF-1 and PACAP in motoneuron-derived cells modelling SBMA. <i>Biophysical Chemistry</i> , 2017, 229, 68-76.	2.8	17
22	Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. <i>Journal of Neuroscience</i> , 2017, 37, 1413-1427.	3.6	42
23	Hydroxy-substituted trans -cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 378-389.	5.5	21
24	Mutations in TGM6 induce the unfolded protein response in SCA35. <i>Human Molecular Genetics</i> , 2017, 26, 3749-3762.	2.9	36
25	Extracellular Vesicles and a Novel Form of Communication in the Brain. <i>Frontiers in Neuroscience</i> , 2016, 10, 127.	2.8	144
26	In Vitro and In Vivo Modeling of Spinal and Bulbar Muscular Atrophy. <i>Journal of Molecular Neuroscience</i> , 2016, 58, 365-373.	2.3	18
27	Anthelmintic Benzimidazoles Are Novel HIF Activators That Prevent Oxidative Neuronal Death via Binding to Tubulin. <i>Antioxidants and Redox Signaling</i> , 2015, 22, 121-134.	5.4	17
28	Protein Arginine Methyltransferase 6 Enhances Polyglutamine-Expanded Androgen Receptor Function and Toxicity in Spinal and Bulbar Muscular Atrophy. <i>Neuron</i> , 2015, 85, 88-100.	8.1	89
29	Correction: Sleiman et al., Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Can Mediate Neuroprotection Independent of HDAC Inhibition. <i>Journal of Neuroscience</i> , 2015, 35, 438-438.	3.6	0
30	Serine phosphorylation and arginine methylation at the crossroads to neurodegeneration. <i>Experimental Neurology</i> , 2015, 271, 77-83.	4.1	26
31	Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Can Mediate Neuroprotection Independent of HDAC Inhibition. <i>Journal of Neuroscience</i> , 2014, 34, 14328-14337.	3.6	25
32	A Selective Phenelzine Analogue Inhibitor of Histone Demethylase LSD1. <i>ACS Chemical Biology</i> , 2014, 9, 1284-1293.	3.4	88
33	Looking Above but Not Beyond the Genome for Therapeutics in Neurology and Psychiatry: Epigenetic Proteins and RNAs Find a New Focus. <i>Neurotherapeutics</i> , 2013, 10, 551-555.	4.4	3
34	In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1 α by inhibition of synthesis and not enhanced degradation. <i>Journal of Neuroscience Research</i> , 2013, 91, 1066-1075.	2.9	15
35	Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by antioxidant-metal chelators: From ferroptosis to stroke. <i>Free Radical Biology and Medicine</i> , 2013, 62, 26-36.	2.9	119
36	Transglutaminase is a Therapeutic Target for Oxidative Stress, Excitotoxicity and Stroke: A new Epigenetic Kid on the Cns Block. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 809-818.	4.3	28

#	ARTICLE	IF	CITATIONS
37	Nitration of Hsp90 induces cell death. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E1102-11.	7.1	122
38	Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes. Journal of Biological Chemistry, 2013, 288, 15699-15711.	3.4	216
39	Transglutaminase Inhibition Protects against Oxidative Stress-Induced Neuronal Death Downstream of Pathological ERK Activation. Journal of Neuroscience, 2012, 32, 6561-6569.	3.6	62
40	Targeting Transcriptional Dysregulation in Huntington's Disease: Description of Therapeutic Approaches. , 2012, , .		1
41	Development of Neh2-Luciferase Reporter and Its Application for High Throughput Screening and Real-Time Monitoring of Nrf2 Activators. Chemistry and Biology, 2011, 18, 752-765.	6.0	92
42	Mithramycin Is a Gene-Selective Sp1 Inhibitor That Identifies a Biological Intersection between Cancer and Neurodegeneration. Journal of Neuroscience, 2011, 31, 6858-6870.	3.6	114
43	Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration. Pharmaceuticals, 2011, 4, 1183-1195.	3.8	21
44	Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Molecular Medicine, 2010, 2, 349-370.	6.9	124
45	Utilization of an In Vivo Reporter for High Throughput Identification of Branched Small Molecule Regulators of Hypoxic Adaptation. Chemistry and Biology, 2010, 17, 380-391.	6.0	68
46	Cu,Zn-Superoxide Dismutase Increases Toxicity of Mutant and Zinc-deficient Superoxide Dismutase by Enhancing Protein Stability*. Journal of Biological Chemistry, 2010, 285, 33885-33897.	3.4	37
47	HIF Prolyl Hydroxylase Inhibitors Prevent Neuronal Death Induced by Mitochondrial Toxins: Therapeutic Implications for Huntington's Disease and Alzheimer's Disease. Antioxidants and Redox Signaling, 2010, 12, 435-443.	5.4	61
48	Characterization of Detergent-Insoluble Proteins in ALS Indicates a Causal Link between Nitritative Stress and Aggregation in Pathogenesis. PLoS ONE, 2009, 4, e8130.	2.5	101
49	Nitroproteomics of Peripheral Blood Mononuclear Cells from Patients and a Rat Model of ALS. Antioxidants and Redox Signaling, 2009, 11, 1559-1567.	5.4	35
50	Putting the "HAT" back on survival signalling: the promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opinion on Investigational Drugs, 2009, 18, 573-584.	4.1	70
51	Gene expression and protein localization of calmodulin-dependent phosphodiesterase during ontogenesis of chick retina. Journal of Neuroscience Research, 2008, 86, 1017-1023.	2.9	6
52	Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochemical and Biophysical Research Communications, 2007, 353, 719-725.	2.1	72
53	Redox regulation of cyclophilin A by glutathionylation. Proteomics, 2006, 6, 817-825.	2.2	43
54	Gene expression and protein localization of calmodulin-dependent phosphodiesterase in adult rat retina. Journal of Neuroscience Research, 2006, 84, 1020-1026.	2.9	15

#	ARTICLE	IF	CITATIONS
55	Insoluble Mutant SOD1 Is Partly Oligoubiquitinated in Amyotrophic Lateral Sclerosis Mice. Journal of Biological Chemistry, 2006, 281, 33325-33335.	3.4	86
56	Protein Nitration in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Journal of Biological Chemistry, 2005, 280, 16295-16304.	3.4	168
57	Proteomics as a tool to improve investigation of substantial equivalence in genetically modified organisms: The case of a virus-resistant tomato. Proteomics, 2004, 4, 193-200.	2.2	90
58	Proteome analysis of human substantia nigra in Parkinson's disease. Proteomics, 2004, 4, 3943-3952.	2.2	246
59	Proteome analysis of mesencephalic tissues: evidence for Parkinson's disease. Neurological Sciences, 2003, 24, 155-156.	1.9	19
60	Huntingtin-Mediated Axonal Transport Requires Arginine Methylation by PRMT6. SSRN Electronic Journal, 0, , .	0.4	2